Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to test the therapeutic benefit of the compound PYM50028, versus placebo, in treating early-stage Parkinson's disease. Therapeutic benefit will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). It is hypothesised that PYM50028 will be safe and well tolerated in this study and demonstrate therapeutic benefit in this patient population.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Phytopharm

Criteria

Inclusion Criteria:

• confirmed diagnosis of early-stage idiopathic PD within the 2 years prior to screening

• subjects who are not currently receiving any PD treatment

Exclusion Criteria:

• female of child-bearing potential

• history of neurosurgical procedures for PD

• history of severe psychiatric illness